Page last updated: 2024-08-22

tiletamine hydrochloride and mk 2206

tiletamine hydrochloride has been researched along with mk 2206 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bowcock, A; DeSelm, C; Grigsby, PW; Helms, C; Rader, J; Rader, JL; Rashmi, R; Rogers, BE; Schwarz, JK	1

Other Studies

1 other study(ies) available for tiletamine hydrochloride and mk 2206

Article	Year
AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. PloS one, 2014, Volume: 9, Issue:4 Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cyclohexanones; Female; Glucose; Heterocyclic Compounds, 3-Ring; Humans; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; TOR Serine-Threonine Kinases; Uterine Cervical Neoplasms	2014

Article

Year

AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake.

PloS one, 2014, Volume: 9, Issue:4

Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cyclohexanones; Female; Glucose; Heterocyclic Compounds, 3-Ring; Humans; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; TOR Serine-Threonine Kinases; Uterine Cervical Neoplasms

2014